TP与GP方案治疗晚期非小细胞肺癌的临床对照研究

A Study of Clinical Contrast of TP and GP Projects in Treatment of Cases with Advanced Non-Small Cell Lung Cancer

目的 评价TP方案（多西他赛TXT，顺铂DDP）与GP方案（吉西他滨GEM，顺铂DDP）治疗晚期非小细胞肺癌（NSCLC）的疗效及毒副反应。方法 82例不能手术的晚期非小细胞肺癌患者随机分为二组，分别采用TP方案和GP方案化疗。结果 TP组和GP组化疗方案有效率分别为47．5％（19／40）及50．o％（21／42），两组中位无进展时间分别为5．5个月和6个月，中位生存时间分别为10．5个月和10．8个月，1年生存率分别为40．O％（16／40）和42．8％（18／42），经统计学处理，两组无显著差异，两组均显示初治比复治疗效好。骨髓抑制为剂量限制性毒性，恶心、呕吐等消化道反应以Ⅰ～Ⅱ度为主。结论 TP及GP方案治疗晚期非小细胞肺癌，疗效相当，毒副反应均可耐受，都可以作为一线首选的化疗方案。

Objective To appraise the therapeutic effect and adverse-side reaction of TP project（docetaxel, diamminedichloroplatinum） and GP（ Gemcitabine, diamminedichloroplatinum） in advanced stage of NSCLC. Methods 82 patients with inoperable NSCLC were divided into two groups of random, each group adopted chemotherapy of TP or GP project. Results The effective power of TP group was 47.5% and GP group was 50.0% , the meso-time of the nonadvanced in TP group was 5.5 months and the other was 6 months, and the meso-live time was 10.5 months and 10.8 months, and the 1 year survival rate was 40.0% and 42.8%. The statistics dealing showed that the two groups had no significant deviation, and the two groups showed that initial treatment was better than retreatment. Bone marrow depression was dose-limiting toxicity and the digestive tract such as sicchasia, emesia,etc, were Ⅰ - Ⅱ grade mainly. Conclusions The therapeutic effect in TP and GP projects to treat advanced stage of NSCLC were same. The patients can tolerate the adverse-side reaction. The two projects can be as the first chemotherapy project.